fibrosis drug development
idiopathic pulmonary fibrosis
high-throughput screening of antifibrotics Liver fibrosis
animal models of induced fibrosis
use of proline derivatives
high-throughput screening of new antifibrotic therapeutics
new antifibrotic drugs
cell-based system
biosynthesis of collagen
hepatic stellate cells
cellular model
approach
efficacy
commercial available library of compounds
excess collagen production
cell-based assay
label collagen structures
known preclinical antifibrotic activities
enormous health burden responsible
fluorescent probe
intracellular proteins
heart failure
fluorescent tetrazine
World Health Organization
increased deposition of extracellular matrix proteins
hepatitis B
demand Diels-Alder reaction
diabetic nephropathy
lungs
reactive handles
key
proposed inverse-electron
chronic diseases
kidney
collagens
proof of principle
vasculature
millions death
nonspecific reactions
cirrhosis
year
alkene
feature
labelling
common outcome
metabolic incorporation
preliminary results
level of selectivity
tissue function
best candidate
pathologies
findings